-
A phase 1 trial of the MEK inhibitor selumetinib in combination with pembrolizumab for advanced or metastatic solid tumors Invest. New Drugs (IF 3.4) Pub Date : 2024-03-14 Maxime Chénard-Poirier, Aaron R. Hansen, Martin E. Gutierrez, Drew Rasco, Yan Xing, Lin-Chi Chen, Heng Zhou, Andrea L. Webber, Tomoko Freshwater, Manish R. Sharma
-
Impact of carbamazepine on SMARCA4 (BRG1) expression in colorectal cancer: modulation by KRAS mutation status Invest. New Drugs (IF 3.4) Pub Date : 2024-03-06 Aaron Shaykevich, Danbee Chae, Isaac Silverman, Jeremy Bassali, Netanel Louloueian, Alexander Siegman, Gargi Bandyopadhyaya, Sanjay Goel, Radhashree Maitra
-
A multicenter phase Ia study of AbGn-107, a novel antibody–drug conjugate, in patients with advanced gastrointestinal cancer Invest. New Drugs (IF 3.4) Pub Date : 2024-03-05
Summary AbGn-107 is an antibody–drug conjugate directed against AG-7 antigen, a Lewis A-like glycol-epitope expressed in a variety of gastrointestinal (GI) malignancies. Based on promising antitumor activity of AbGn-107 in both in vitro and in vivo preclinical studies, we performed a GI cancer-specific Phase I trial. Standard 3 + 3 dose escalation was used evaluating intravenous doses ranging from
-
The novel cytotoxic polybisphosphonate osteodex decreases bone resorption by enhancing cell death of mature osteoclasts without affecting osteoclastogenesis of RANKL-stimulated mouse bone marrow macrophages Invest. New Drugs (IF 3.4) Pub Date : 2024-03-01 Petra Henning, Anna Westerlund, Sofia Movérare-Skrtic, Catharina Lindholm, Marcela Márquez-Méndez, Sten Nilsson, Anders R. Holmberg, Ulf H. Lerner
-
First-line treatment of driver gene-negative metastatic lung adenocarcinoma with malignant pleural effusion: Should chemotherapy be combined with an immune checkpoint inhibitor or bevacizumab? Invest. New Drugs (IF 3.4) Pub Date : 2024-02-22 Yuanyuan Zhao, Ting Mei, Feifei Na, Xiaoman Tian, Rui Ao, Xiangyu Long, Qiang Luo, Ping Duan, Jiang Zhu, Yongsheng Wang, Meijuan Huang, Yongmei Liu, Youling Gong
-
A phase 1b open-label study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of py314 in combination with pembrolizumab in patients with advanced renal cell carcinoma Invest. New Drugs (IF 3.4) Pub Date : 2024-02-19 Kathryn E. Beckermann, Amita Patnaik, Ira Winer, Winston Tan, Babar Bashir, Christos E. Kyriakopoulos, Randy F. Sweis, Marc Chamberlain, Brian I. Rini
-
Targeting LEF1-mediated epithelial-mesenchymal transition reverses lenvatinib resistance in hepatocellular carcinoma Invest. New Drugs (IF 3.4) Pub Date : 2024-02-19 Xinxiu Li, Hongmeng Su, Wenqing Tang, Shihui Shu, Luyu Zhao, Jinghan Sun, Hong Fan
-
Safety and efficacy of apatinib in combination with chemotherapy with or without immunotherapy versus chemotherapy alone as first-line treatment for advanced gastric cancer Invest. New Drugs (IF 3.4) Pub Date : 2024-02-17 Lele Chang, Xuemei Zhang, Qian Ma, Lingyang Kong, Yang Yu, Ji Tao, Qingwei Li
-
PD-1 inhibitor combined with albumin paclitaxel and apatinib as second-line treatment for patients with metastatic gastric cancer: a single-center, single-arm, phase II study Invest. New Drugs (IF 3.4) Pub Date : 2024-02-12 Miaomiao Gou, Yong Zhang, Zhikuan Wang, Niansong Qian, Guanghai Dai
-
CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial Invest. New Drugs (IF 3.4) Pub Date : 2024-02-07 Andrew J. Armstrong, Ravit Geva, Hyun Cheol Chung, Charlotte Lemech, Wilson H. Miller Jr., Aaron R. Hansen, Jong-Seok Lee, Frank Tsai, Benjamin J. Solomon, Tae Min Kim, Christian Rolfo, Vincent Giranda, Yixin Ren, Fang Liu, Bhargava Kandala, Tomoko Freshwater, Judy S. Wang
-
Phase 1 study of pembrolizumab plus chemotherapy in Japanese patients with extensive-stage small-cell lung cancer Invest. New Drugs (IF 3.4) Pub Date : 2024-02-01 Naoyuki Nogami, Takaaki Tokito, Yoshitaka Zenke, Miyako Satouchi, Takashi Seto, Hideo Saka, Junko Ohtani, Shirong Han, Kazuo Noguchi, Makoto Nishio
-
Phase 1 trial of navitoclax and sorafenib in patients with relapsed or refractory solid tumors with hepatocellular carcinoma expansion cohort Invest. New Drugs (IF 3.4) Pub Date : 2024-01-25 Oluwadunni E. Emiloju, Jun Yin, Emily Koubek, Joel M. Reid, Mitesh J. Borad, Yanyan Lou, Mahesh Seetharam, Martin J. Edelman, Edward A. Sausville, Yixing Jiang, Ahmed O. Kaseb, James A. Posey, Sarah L. Davis, Gregory J. Gores, Lewis R. Roberts, Naoko Takebe, Gary K. Schwartz, Andrea E. Wahner Hendrickson, Scott H. Kaufmann, Alex A. Adjei, Joleen M. Hubbard, Brian A. Costello
-
Clinical characteristics, diagnosis and management of nivolumab-induced myocarditis Invest. New Drugs (IF 3.4) Pub Date : 2024-01-23
Summary Nivolumab can cause fatal myocarditis. We aimed to analyze the clinical characteristics of nivolumab-induced myocarditis and provide evidence for clinical diagnosis, treatment, and prevention. Studies involving nivolumab-induced myocarditis were identified in electronic databases from 2000 to 2023 for retrospective analysis. A total of 66 patients were included, with a median age of 68 years
-
A bispecific antibody targeting HER2 and CLDN18.2 eliminates gastric cancer cells expressing dual antigens by enhancing the immune effector function Invest. New Drugs (IF 3.4) Pub Date : 2024-01-10 Jingying Yue, Shuai Shao, Jie Zhou, Wenting Luo, Yanling Xu, Qinbin Zhang, Jing Jiang, Marie M Zhu
-
Targeted delivery of liposomal Ribociclib to SLC7A5 transporters in breast cancer cells Invest. New Drugs (IF 3.4) Pub Date : 2023-12-21
Summary This study aimed to prepare SLC7A5 transporters targeted liposomes of Ribociclib (RB) by stear(o)yl conjugation of Phe, Asp, Glu amino acids to liposomes as targeting moieties. The liposomes were optimized for their formulations. Cell analysis on two cell lines of MCF-7 and NIH-3T3 were done including; cell viability test by MTT assay, cellular uptake, and cell cycle arrest by flow cytometry
-
Effects of food and ethnicity on the pharmacokinetics of venadaparib, a next-generation PARP inhibitor, in healthy Korean, Caucasian, and Chinese male subjects Invest. New Drugs (IF 3.4) Pub Date : 2023-12-15 Hyun Chul Kim, Eunsol Yang, Soyoung Lee, Jaeseong Oh, Myongjae Lee, ChaeEun Lee, Kyoung Soo Ha, Won Sik Lee, In-Jin Jang, Kyung-Sang Yu
-
Synergistic effect of adavosertib and fimepinostat on acute myeloid leukemia cells by enhancing the induction of DNA damage Invest. New Drugs (IF 3.4) Pub Date : 2023-12-12 Yue Wang, Xingyu Lin, Yue Wang, Guan Wang
-
RPTOR mutation: a novel predictor of efficacious immunotherapy in melanoma Invest. New Drugs (IF 3.4) Pub Date : 2023-12-10 Yanfang Jiang, Xintong Hu, Zhouyu Wang, Qin Zhang, Dongsheng Chen, Pingwei Zhao
-
Clinical characteristics, diagnosis, treatment, and prognosis of nivolumab induced gastritis Invest. New Drugs (IF 3.4) Pub Date : 2023-12-08 Haibo Lei, Wei Sun, Xiang Liu, Chunjiang Wang
Gastritis has recently been reported to be associated with nivolumab, and the clinical characteristics of nivolumab induced gastritis remain unclear. To explore the clinical characteristics of nivolumab induced gastritis, and to provide reference for the classification and treatment guidelines of immune checkpoint inhibitors -related gastritis. Case reports, case series, and clinical studies of nivolumab
-
A multicenter phase II trial of the triplet antiemetic therapy with palonosetron, aprepitant, and olanzapine for a cisplatin-containing regimen. - PATROL-I- Invest. New Drugs (IF 3.4) Pub Date : 2023-12-06 Daiki Tsuji, Shigeru Nakagaki, Itsuki Yonezawa, Kenichi Suzuki, Takashi Yokokawa, Yohei Kawasaki, Takumi Yamaguchi, Takashi Kawaguchi, Masahiro Hatori, Takuma Matsumoto, Yukio Sakata, Keisuke Yamamoto, Tomoyasu Nishimura, Yuki Kogure, Toshinobu Hayashi, Misa Osawa, Kunihiko Itoh, Masaya Watanabe
-
Phase I/II trial of BMS-986,205 and nivolumab as first line therapy in hepatocellular carcinoma Invest. New Drugs (IF 3.4) Pub Date : 2023-12-01 Jasmine C. Huynh, May Cho, Arta Monjazeb, Ebaa Al-Obeidi, Amisha Singh, Kit Tam, Frances Lara, Anthony Martinez, Leslie Garcia, Edward J. Kim
-
Endosomal recycling inhibitors downregulate the androgen receptor and synergise with enzalutamide Invest. New Drugs (IF 3.4) Pub Date : 2023-11-14 Kelsey A. Fletcher, Mai H. Alkurashi, Andrew J. Lindsay
-
Immunoneoadjuvant therapy with immune checkpoint inhibitors of gastric cancer: an emerging exemplification Invest. New Drugs (IF 3.4) Pub Date : 2023-11-16 Guoliang Yao, Jianyong Yuan, Qianqian Duan, Yuan Tan, Qin Zhang, Dongsheng Chen, Jingbo Chen
-
Molecular profiling and prognostic analysis in Chinese cholangiocarcinoma: an observational, retrospective single-center study Invest. New Drugs (IF 3.4) Pub Date : 2023-11-17 Changkun Zhang, Xia You, Qin Zhang, Dong Wang
-
The ATR inhibitor berzosertib acts as a radio- and chemosensitizer in head and neck squamous cell carcinoma cell lines Invest. New Drugs (IF 3.4) Pub Date : 2023-11-07 Julia Schnoell, Carmen Sparr, Sega Al-Gboore, Markus Haas, Faris F. Brkic, Lorenz Kadletz-Wanke, Gregor Heiduschka, Bernhard J. Jank
-
Clinical characteristics and prognostic impact of immune checkpoint inhibitor-associated myocarditis in advanced non-small cell lung cancer Invest. New Drugs (IF 3.4) Pub Date : 2023-10-30 Lan Xu, Manyi Xu, Wei Sun, Weiping Zhang, Zhengbo Song
-
Clinical characteristics, treatment, and management of pembrolizumab induced hemophagocytic lymphohistiocytosis Invest. New Drugs (IF 3.4) Pub Date : 2023-10-28 Chunjiang Wang, Wei Sun, Zuojun Li, Tian Wu, Weijin Fang
Background Hemophagocytic lymphohistiocytosis (HLH) is a rare and fatal adverse reaction to pembrolizumab. The clinical characteristics of pembrolizumab induced HLH are unknown. Exploring the clinical features of pembrolizumab induced HLH is crucial for the treatment and prevention of immune checkpoint inhibitor-induced HLH. Methods The literature related to pembrolizumab induced HLH was collected
-
Pharmacokinetics, pharmacodynamics and efficacy of pemigatinib (a selective inhibitor of fibroblast growth factor receptor 1–3) monotherapy in Chinese patients with advanced solid tumors: a phase i clinical trial Invest. New Drugs (IF 3.4) Pub Date : 2023-10-27 Ting Deng, Le Zhang, Yehui Shi, Guiying Bai, Yueyin Pan, Aizong Shen, Xinghua Han, Zhaoyi Yang, Mingxia Chen, Hui Zhou, Yang Luo, Shirui Zheng, Yi Ba
-
Gastrointestinal signet ring cell malignancy: current advancement and future prospects Invest. New Drugs (IF 3.4) Pub Date : 2023-10-21 Weiping Hong, Qingjun Hu, Yuan Tan, Qianqian Duan, Qin Zhang, Dongsheng Chen, Chuang Qi, Da Wang
-
Antitumor activity of the new tyrphostin briva against BRAFV600E-mutant colorectal carcinoma cells Invest. New Drugs (IF 3.4) Pub Date : 2023-10-23 Khaled Saleh, Mai Al Sakhen, Sana Kanaan, Salem Yasin, Michael Höpfner, Lubna Tahtamouni, Bernhard Biersack
-
Optimal first-line treatment strategies of systemic therapy for unresectable gastrointestinal neuroendocrine tumors based on the opinions of Japanese experts. Invest. New Drugs (IF 3.4) Pub Date : 2023-10-19 Yoshitaka Honma, Masafumi Ikeda, Susumu Hijioka, Shigemi Matsumoto, Tetsuhide Ito, Taku Aoki, Junji Furuse
-
Gefitinib, an effective treatment option for patients with pulmonary enteric adenocarcinoma harboring compound EGFR L858R and A871G mutation Invest. New Drugs (IF 3.4) Pub Date : 2023-10-13 Yujie Cui, Jinlong Liang, Xiyun Kang, Miaomiao Liu, Qi Zhang, Hongzhen Zhang
-
Therapeutic effectiveness of anlotinib combined with etoposide in extensive-stage small-cell lung cancer: a single-arm, phase II trial Invest. New Drugs (IF 3.4) Pub Date : 2023-10-14 Yuan Wu, Xuefeng Zhou, Weiqing Zhao, Qiong Wang, Zhengxiang Han, Lifeng Wang, Wenjie Zhou, Tong Zhou, Haizhu Song, Yong Chen, Kaihua Yang, Lin Shi, Banzhou Pan, Renhong Guo, Guoren Zhou, Feng Jiang, Jifeng Feng, Bo Shen
-
Phase 1/1b open-label, dose-escalation study of fruquintinib in patients with advanced solid tumors in the United States Invest. New Drugs (IF 3.4) Pub Date : 2023-10-05 Andrea Wang-Gillam, William Schelman, Stacey Ukrainskyj, Caly Chien, Martha Gonzalez, Zhao Yang, Marek Kania, Heather Yeckes-Rodin
-
Clinical characterization, treatment, and outcome of nivolumab-induced bullous pemphigoid Invest. New Drugs (IF 3.4) Pub Date : 2023-09-29 Miao Liu, Maoye Yuan, Wei Sun, Zuojun Li, Xingchen Zhou, Chunjiang Wang
Background Bullous pemphigoid (BP) is a serious and rare complication of nivolumab. This study aimed to explore the clinical characteristics of nivolumab-induced BP and provide a reference for prevention and treatment of BP. Methods Literature on nivolumab-induced BP was collected for retrospective analysis by searching both Chinese and English databases as of July 31, 2023. Results Sixty patients
-
Safety and blood levels of daratumumab after switching from intravenous to subcutaneous administration in patients with multiple myeloma Invest. New Drugs (IF 3.4) Pub Date : 2023-09-18 Kenta Yamaoka, Kei Irie, Nobuhiro Hiramoto, Masaki Hirabatake, Hiroaki Ikesue, Tohru Hashida, Tadashi Shimizu, Takayuki Ishikawa, Nobuyuki Muroi
-
A novel anticancer quinolone, (R)-WAC-224, has anti-leukemia activities against acute myeloid leukemia Invest. New Drugs (IF 3.4) Pub Date : 2023-09-13 Tatsuji Mino, Hiroshi Ureshino, Taichi Ueshima, Naoki Kashimoto, Tomonori Yamaguchi, Kazuhito Naka, Toshiya Inaba, Tatsuo Ichinohe
-
A novel bivalent anti-c-MET/PD-1 bispecific antibody exhibits potent cytotoxicity against c-MET/PD-L1-positive colorectal cancer Invest. New Drugs (IF 3.4) Pub Date : 2023-08-30 Z. Sun, C. Gu, X. Wang, A. Shang, W. Quan, J. Wu, P. Ji, Y. Yao, W. Liu, D. Li
-
The efficacy and safety of selective RET inhibitors in RET fusion-positive non-small cell lung cancer: a meta-analysis Invest. New Drugs (IF 3.4) Pub Date : 2023-08-21 Jun-yi Ke, Shu Huang, Zhi-tao Jing, Min-chao Duan
-
Early on-treatment C-reactive protein and its kinetics predict survival and response in recurrent and/or metastatic head and neck cancer patients receiving first-line pembrolizumab Invest. New Drugs (IF 3.4) Pub Date : 2023-08-21 Markus Haas, Alexander Lein, Thorsten Fuereder, Julia Schnoell, Faris F. Brkic, David T. Liu, Lorenz Kadletz-Wanke, Gregor Heiduschka, Bernhard J. Jank
-
Clinical characteristics of liver injury induced by immune checkpoint inhibitors in patients with advanced biliary tract carcinoma Invest. New Drugs (IF 3.4) Pub Date : 2023-08-17 Zhao Gao, Shikai Wu, Yinmo Yang, Mingxia Sun, Xiaodong Tian, Xuan Jin
Immune-related liver injuries are closely associated with the liver’s fundamental state. Patients with advanced biliary tract carcinoma (BTC) have poor liver function. We evaluated the clinical data of immune-related liver injury in patients with advanced BTC and gastric cancer (GC) during immune checkpoint inhibitor (ICI) treatment between February 2019 and July 2022 at Peking University First Hospital
-
Efficacy, safety, and cost-minimization analysis of axicabtagene ciloleucel and tisagenlecleucel CAR T-Cell therapies for treatment of relapsed or refractory follicular lymphoma Invest. New Drugs (IF 3.4) Pub Date : 2023-08-12 Buthainah Ghanem
-
Preclinical evaluation of the VEGF/Ang2 bispecific nanobody BI 836880 in nasopharyngeal carcinoma models Invest. New Drugs (IF 3.4) Pub Date : 2023-08-12 Rachel C.T. Lam, Connie W.C. Hui, C. H. Wong, K. W. Lo, Anna C.M. Tsang, Edwin P. Hui, Anthony T.C. Chan, Brigette B.Y. Ma
-
Lurbinectedin in patients with pretreated endometrial cancer: results from a phase 2 basket clinical trial and exploratory translational study Invest. New Drugs (IF 3.4) Pub Date : 2023-08-09 Rebecca Kristeleit, Alexandra Leary, Jean Pierre Delord, Victor Moreno, Ana Oaknin, Daniel Castellano, Geoffrey I. Shappiro, Cristian Fernández, Carmen Kahatt, Vicente Alfaro, Mariano Siguero, Daniel Rueda, Ali Zeaiter, Ahmad Awada, Ana Santaballa, Khalil Zaman, Jalid Sehouli, Vivek Subbiah
-
Cytotoxicity of poly-guanidine in medulloblastoma cell lines Invest. New Drugs (IF 3.4) Pub Date : 2023-08-09 Gabriel Gallo-Oller, Teresita Díaz de Ståhl, Ayodele Alaiya, Sten Nilsson, Anders R. Holmberg, Marcela Márquez-Méndez
-
Enhanced antitumor and anti-metastasis by VEGFR2-targeted doxorubicin immunoliposome synergy with NK cell activation Invest. New Drugs (IF 3.4) Pub Date : 2023-08-05 Mingzhu Pan, Yali Liu, Tian Sang, Jiajun Xie, Huishu Lin, Jianpeng Wei, Shuai Shao, Yanying Zheng, Juan Zhang
-
Development and characterization of fused human arginase I for cancer therapy Invest. New Drugs (IF 3.4) Pub Date : 2023-08-03 Snehal Sainath Jawalekar, Priyanka Sugriv Kawathe, Nisha Sharma, J Anakha, Kulbhushan Tikoo, Abhay H. Pande
-
Development of novel palbociclib-based CDK4/6 inhibitors exploring the back pocket behind the gatekeeper Invest. New Drugs (IF 3.4) Pub Date : 2023-07-20 Lina Li, Fengquan Chen, Mengzhe Li, Yongxiang Liao, Yongjie Wang, Wen Jiang, Yun Luan, Xia Xue
-
Pharmacological assessment of the antineoplastic and immunomodulatory properties of a new spiroindolone derivative (7’,8’-Dimethoxy-1’,3’-dimethyl-1,2,3’,4’-tetrahydrospiro[indole-3,5’-pyrazolo[3,4-c]isoquinolin]-2-one) in chronic myeloid leukemia Invest. New Drugs (IF 3.4) Pub Date : 2023-07-15 Carlos Eduardo de Castro Alves, Serge L. Bogza, Nathalie Bohdan, Alexander B. Rozhenko, Alice de Freitas Gomes, Regiane Costa de Oliveira, Renata Galvão de Azevedo, Larissa Raquel Silva Maciel, Anamika Dhyani, Andriy Grafov, Gemilson Soares Pontes
-
Idarubicin versus epirubicin in drug-eluting beads-transarterial chemoembolization for treating hepatocellular carcinoma: A real-world retrospective study Invest. New Drugs (IF 3.4) Pub Date : 2023-07-12 Chenghao Zhao, Huzheng Yan, Zhanwang Xiang, Haofan Wang, Mingan Li, Mingsheng Huang
-
Indirect comparisons of efficacy of zanubrutinib versus orelabrutinib in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma or relapsed or refractory mantle cell lymphoma Invest. New Drugs (IF 3.4) Pub Date : 2023-07-08 Yuqin Song, Keshu Zhou, Shenmiao Yang, Jianda Hu, Dehui Zou, Sujun Gao, Ling Pan, Tingyu Wang, Haiyan Yang, Huilai Zhang, Daobin Zhou, Jie Ji, Wei Xu, Ru Feng, Jie Jin, Fangfang Lv, Haiwen Huang, Xiaosi Fan, Sheng Xu, Jun Zhu
-
Assessment of the potential of the MET inhibitor tepotinib to affect the pharmacokinetics of CYP3A4 and P-gp substrates Invest. New Drugs (IF 3.4) Pub Date : 2023-07-06 Özkan Yalkinoglu, Andreas Becker, Axel Krebs-Brown, Claudia Vetter, Christian Lüpfert, Dominique Perrin, Jürgen Heuer, Herlind Biedert, Stefan Hirt, Afrim Bytyqi, Angelika Bachmann, Rainer Strotmann
-
The p53 reactivator PRIMA-1MET synergises with 5-fluorouracil to induce apoptosis in pancreatic cancer cells Invest. New Drugs (IF 3.4) Pub Date : 2023-07-04 Ibtehal Mohammed, Ali Haider Alhammer, Inam Sameh Arif
-
Safety and efficacy of immunotherapy plus chemotherapy as neoadjuvant treatment for patients with locally advanced gastric cancer: a retrospective cohort study Invest. New Drugs (IF 3.4) Pub Date : 2023-06-27 Xue Wang, Jinxiang Huang, He Huang, Yang Liu, Chao Ji, Jian Liu
-
Sitravatinib is a potential EGFR inhibitor and induce a new death phenotype in Glioblastoma Invest. New Drugs (IF 3.4) Pub Date : 2023-06-16 Hanwen Lu, Bingchang Zhang, Yuanyuan Xie, Wenpeng Zhao, Wanhong Han, Liwei Zhou, Zhanxiang Wang
-
POTEE mutation as a potential predictive biomarker for immune checkpoint inhibitors in lung adenocarcinoma Invest. New Drugs (IF 3.4) Pub Date : 2023-06-15 Yongzhao Li, Qidong Yang, Yaqin Liu, Huan Yi, Yongzhi Ju, Guoyan Qi
-
A phase I/II study of LY3022855 with BRAF/MEK inhibition in patients with Melanoma Invest. New Drugs (IF 3.4) Pub Date : 2023-05-29 Elizabeth I. Buchbinder, Anita Giobbie-Hurder, Rizwan Haq, Patrick A. Ott
-
Correction to: The kinesin motor protein KIF4A as a potential therapeutic target in renal cell carcinoma Invest. New Drugs (IF 3.4) Pub Date : 2023-05-27 Guihong Liu, Yachun Lu, Liantao Li, Tao Jiang, Sufang Chu, Pingfu Hou, Jin Bai, Ming Chen
-
Degradation of MYC by the mutant p53 reactivator drug, COTI-2 in breast cancer cells Invest. New Drugs (IF 3.4) Pub Date : 2023-05-26 Minhong Tang, John Crown, Michael J Duffy
-
Bispecific anti-CD3×anti-CD155 antibody mediates T-cell immunotherapy in human haematologic malignancies Invest. New Drugs (IF 3.4) Pub Date : 2023-05-17 Li Ma, Juan Ma, Xin Sun, Honggang Liu